PGIM Mutual Fund to launch PGIM India Healthcare Fund

The PGIM India Healthcare Fund, a sector-focused equity mutual fund, will be introduced by PGIM Mutual Fund. The fund primarily invests in equity and equity-related securities in the healthcare and pharmaceutical industries with the goal of achieving long-term capital appreciation. On November 19, 2024, the new fund offer (NFO) will go live.

Scheme for the PGIM India Healthcare Fund

Growth, IDCW (Income Distribution cum Capital Withdrawal), and IDCW-Reinvestment options are among the open-ended plans available under the scheme. A 0.50% exit load is applied if the investment is redeemed within 30 days, and the minimum investment amount is Rs 5,000 with no entry load. Mr Anandha Padmanabhan will oversee the fund, which intends to diversify across several healthcare industries, including pharmaceuticals, healthcare services, diagnostics, and medical devices.

Regular Plan for the PGIM India Healthcare Fund

Net Asset Value (NAV): The PGIM India Healthcare Fund’s Regular Plan (Growth option) does not currently have an NAV available.

Returns:

There is no specific mention of the fund’s trailing returns over various time periods. For comparison, the healthcare industry’s category returns over the same time period are remarkable:

1-Year Return: 54.65%

3-Year Return: 19.33%

5-Year Return: 27.75%

Fund Size: As of the most recent data available, the fund’s assets under management (AUM) have not been disclosed.

Expense Ratio: The expense ratio applicable to the Regular Plan of this fund is not currently available.

Exit Load: A 0.50 per cent exit load will be applied if the money is withdrawn within 90 days of the investment date.

Requirements for Investment:

The minimum initial investment is Rs. 5,000.

Rs. 1,000 is the minimum additional investment.

Rs. 1,000 is the minimum SIP investment.

Summary

Exposure to the changing healthcare landscape in India is the goal of the PGIM India Healthcare Fund-Regular Plan. The focus on pharmaceuticals, healthcare services, diagnostics, and related segments makes it an appealing choice for long-term, high-risk tolerance investors, even though specific performance metrics like NAV and AUM data are still pending. The competitive category returns reflect the potential for high growth in this space, but it’s important for investors to consider the associated risks.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.